Naloxone Auto-Injector Formulation for Rapid Opioid Reversal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current remedies for opioid exposure, particularly aerosolized opioids, lack a fast-acting and easily deployable solution for immediate use in various settings, including medical and community environments, and there is a need for a stable formulation of opioid antagonists like naloxone that can be self-administered or administered by non-medical professionals.
Innovation Solution
Development of pharmaceutical dosage formulations and devices containing naloxone, including pre-loaded auto-injector devices, with specific concentrations of naloxone, isotonicity agents, preservatives, and stabilizing agents, designed for single-use or multi-dose delivery via injection or intranasal administration, providing a stable and effective treatment for opioid exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If naloxone is packaged for individual or community use, then ease of operation is improved, but device complexity increases
Solution Approach 1:
The naloxone formulation is segmented into pre-measured dosage units within the auto-injector device, allowing for simple single-dose or multi-dose administration without requiring complex preparation steps by the user
Solution Approach 2:
The auto-injector device is designed for self-administration by individuals or non-medical professionals, eliminating the need for medical personnel to prepare and administer the medication, thereby improving ease of operation while maintaining controlled complexity through automated delivery mechanisms
2Reliability
If a stable formulation of naloxone is developed, then reliability is improved, but manufacturing precision requirements increase
Solution Approach 1:
The formulation employs specific concentration ranges of naloxone (0.3%-3.0% w/v) combined with isotonicity agents, preservatives, and stabilizing agents to achieve optimal stability while maintaining manufacturability through well-established pharmaceutical processing parameters
Solution Approach 2:
The naloxone formulation is developed as a composite pharmaceutical composition incorporating multiple components (naloxone, NaCl, BZK, EDTA, citric acid) that work synergistically to enhance stability while allowing for robust manufacturing processes with standardized precision requirements
3Speed
If fast-acting formulation is developed for immediate use, then speed of action is improved, but formulation complexity increases
Solution Approach 1:
The auto-injector device is pre-loaded with the naloxone formulation in ready-to-administer syringes or cartridges, eliminating preparation time and enabling immediate injection or intranasal delivery when opioid exposure occurs
Solution Approach 2:
The active naloxone ingredient is extracted and isolated in a pure, concentrated formulation within the auto-injector device, ensuring rapid delivery of the therapeutic agent without the need for complex compounding or preparation procedures
Data Source
AI summary
The present disclosure relates to pharmaceutical compositions comprising an opioid antagonist, isotonicity agent, a preservative agent, a stabilizing agent and citric acid. The pharmaceutical compositions are stable under various storage conditions. Methods of using the pharmaceutical compositions are also disclosed including methods of treatment